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Objectives:Depression is frequently observed in patients with systemic lupus erythematosus (SLE). Neuropsychi-
atric SLE (NPSLE) patients often exhibit cerebral hypometabolism, but the association between cerebral metab-
olism and depression remains unclear. To elucidate the features of cerebral metabolism in SLE patients with
depression, we performed brain 18F-ﬂuoro-D-glucose positron emission tomography (FDG-PET) on SLE patients
with and without major depressive disorder.
Methods:We performed brain FDG-PET on 20 SLE subjects (5 male, 15 female). The subjects were divided into
two groups: subjects with major depressive disorder (DSLE) and subjects without major depressive disorder
(non-DSLE). Cerebral glucose metabolismwas analyzed using the three-dimensional stereotactic surface projec-
tion (3D-SSP) program. Regionalmetabolismwas evaluated by stereotactic extraction estimation (SEE), inwhich
the whole brain was divided into segments.
Results: Every SLE subject exhibited cerebral hypometabolism, in contrast to the normal healthy subjects. Region-
al analysis revealed a signiﬁcantly lower ER in the left medial frontal gyrus (p = 0.0055) and the right medial
frontal gyrus (p= 0.0022) in the DSLE group than in the non-DSLE group.
Conclusion:Hypometabolism in themedial frontal gyrusmay be related tomajor depressive disorder in SLE. Larg-
er studies are needed to clarify this relationship.
© 2017 Published by Elsevier B.V.
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1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder af-
fecting multiple organs including the central nervous system. Patients
with SLE frequently exhibit neuropsychiatric (NP) manifestations
which range from neurological dysfunction to mental disorders. Al-
though the American College of Rheumatology (ACR) deﬁnes 19 NP
SLE syndromes (NPSLE) [1], the neurobiological differences between
these syndromes are still poorly understood.
Depression is one of the most frequently observed NP disorders in
patients with SLE. The prevalence of depression ranges from 17% to
75%, which is much higher than in the general population [2]. The etiol-
ogy of depression in SLE is highly controversial. While neurological
symptoms can be thought to be caused by biological factors, psychoso-
cial factors are most frequently considered to be the probable cause of
depression in SLE. Although a number of reports have suggested a neu-
robiological pathogenesis, there are no speciﬁc biomarkers to evaluate
depression in SLE [2].
Functional neuroimaging such as positron emission tomography
(PET) is being increasingly used in theﬁeld of neurology and psychiatry.
As far as NPSLE is concerned, previous studies have reported that brain
18F-ﬂuoro-D-glucose PET (FDG-PET) scans frequently reveal a decrease
in cerebral metabolism in SLE patients with NP manifestations [3–5].
Although these reports indicate an association between cerebral
hypometabolism and NPSLE, there have been few brain FDG-PET stud-
ies that focused on depression in SLE.
In order to elucidate the distinctive features of cerebral glucose me-
tabolism in SLE patients with depression, we performed a brain FDG-
PET study on SLE patients with and without major depressive disorder.
These FDG-PET results were statistically analyzed using the three-
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dimensional stereotactic surface projection (3D-SSP) program, which is
commonly used to diagnose dementia by detecting speciﬁc regions of
the brain with altered metabolism [6].
2. Materials and methods
2.1. Subjects
Patients who fulﬁlled the ACR 1997 revised criteria for the classi-
ﬁcation of SLE [7] were recruited at Yokohama City University Hospi-
tal between 2011 and 2014. Patients with developmental disorders
and/or central nervous system diseases except for NP disorders, as
deﬁned by the ACR criteria for NPSLE [1], were excluded. Eventually,
20 SLE subjects (5 male, 15 female) were enrolled in the present
study. Disease activity in SLE was assessed by the SLE Disease Activ-
ity Index (SLEDAI) [8]. The presence of SLE-associated antibodies
such as anti-DNA antibodies, anti-Smith antibodies, anti-cardiolipin
antibodies and lupus anticoagulant was investigated based on their
medical records. Neurological involvement in SLE was evaluated by
clinical examination, cerebrospinal ﬂuid (CSF) testing and brain
magnetic resonance imaging (MRI). Alterations in periventricular
white matter (PVWM) and deep white matter (DWM)were evaluat-
ed according to the Fazekas scale [9]. We performed CSF tests on 19
subjects and calculated the Q albumin (CSF albumin × 1000 /
serum albumin) and IgG index ([CSF IgG × serum albumin] / [CSF al-
bumin × serum IgG]). Interleukin 6 (IL-6) in CSF were examined
among 13 subjects. These are neuroinﬂammatory markers associat-
ed with NPSLE, according to the previous reports [10–12]. The sub-
jects' psychiatric symptoms were assessed by trained psychiatrists
according to the ACR criteria for NPSLE [1] and the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR), and major depressive disorder was determined if they
met the criteria for major depressive disorder of DSM-IV-TR, and also
if the Hamilton Depression Rating Scale-17 (HAMD-17) was above 7
(mild to severe depression) [13]. Cognitive dysfunction was deﬁned
as follows: The cognitive dysfunction interferes with independence
in everyday activities; the score of the Mini-Mental State Examina-
tion (MMSE) was b24, or the full-scale the intelligence quotient
(FIQ) measured by the Wechsler Adult Intelligence Scale - Third Edi-
tion (WAIS-III) was b70. The subjects were then divided into two
groups: subjects with major depressive disorder and SLE (DSLE)
and subjects without major depressive disorder (non-DSLE).Written
informed consent was obtained from all subjects after oral and writ-
ten explanations. The present study was approved by the Institution-
al Ethics Committee of Yokohama City University Hospital.
2.2. FDG-PET
Brain FDG-PET/CT scans were performed using an Aquiduo 16
(Toshiba Medical Systems Corporation, Tochigi, Japan); the mean
trans-axial spatial resolutions at 1.0 and 10 cm, off axis were 6.5 and
6.5 mm, respectively. After intravenous administration of 3.7 MBq/kg/
3.5 ml 18F-FDG, the subjects were kept in an isolation room and
instructed to remain still with their eyes open to avoid falling asleep.
A set of trans-axial images was obtained 60 ± 5 min after the injection
with a scan duration of 5 or 10 min. The images were reconstructed by
attenuation-weighted ordered-subset expectation maximization
(OSEM). The matrix size, slice thickness and number of 18F-FDG-PET
images were 256 × 256 mm, 2.0 mm and 81 or 139 slices, respectively.
2.3. Data analysis
The brain FDG-PET results were analyzed using the NEUROSTAT
3D–SSP program [6]. Cerebral glucose metabolism in each subject
was compared with a normative database consisting of data from
77 normal healthy volunteers (36 male and 41 female) as previous
reported [14,15], and decreased levels of cerebral glucose metabolism
were calculated as a Z-score (normal mean - individual value/normal
SD). A Z-score over 2.0 was considered to be abnormal. Regional cere-
bral glucose metabolism in each subject was quantitatively evaluated
by stereotactic extraction estimation (SEE), in which the whole brain
was divided into segments, based on an anatomical classiﬁcation [16].
We used the hemisphere-level (level 1) and the gyrus-level (level 3)
analysis of the SEE method. The proportion of pixels with a Z-score
over 2.0 in each segment was calculated and expressed as the extent
ratio (ER). The mean value of each ER was compared between the two
groups using a two-tailed t-test with p b 0.05 considered signiﬁcant.
Glucose metabolism was also compared between the DSLE group and
the non-DSLE group using 3D-SSP. In theDSLE group, regions exhibiting
a decrease (Z N 2.0) were displayed on a brain map. SEE methods were
also used to analyze regionally lower levels of cerebral glucosemetabo-
lism in the DSLE group comparedwith the non-DSLE group, and ERwas
calculated for each region at the gyrus level.
3. Results
The demographics of the subjects are shown in Table 1. Age, gender,
and prior and current NP syndromes are shown in Table 2. There were
no differences in age, gender, SLE duration, SLEDAI, the presence of
SLE-associated antibodies, corticosteroid steroid dose (converted into
an equivalent dose of prednisolone) and white matter alterations be-
tween the DSLE and non-DSLE groups. Only Case 8 had antidepressants
(paroxetine 20 mg, trazodone 100 mg) for maintenance treatment in
MDD, but the other subjects did not have antidepressants. At the time
of this study, there were no subjects in the DSLE group with NP syn-
dromes, except for major depressive disorder. However, in the non-
DSLE group, 2 subjects displayed cognitive dysfunction while 11 of the
13 subjects exhibited no NP syndromes.
Compared with a normative database [14], decrease in cerebral
glucose metabolism in each subject was calculated as a Z-score,
and displayed on a brain map (see Supplementary File). The mean
ER, the ratio of decreased areas (Z N 2.0) in each segment, is presented
in Table 3. In the present study, every SLE subject exhibited
hypometabolism in the cerebrum. The gyrus-level analysis revealed
that subjects in the DSLE group had 50 segments with hypometabolism
(ER N 0%) out of a total of 62 segments. Therewere 21 segmentswith an
ER over 10%. A comparison between the DSLE and non-DSLE groups
showed no signiﬁcant difference in ER in the hemisphere-level analysis.
However, in the gyrus-level analysis, the mean value of ER was
Table 1
Patient demographics (mean values ± SD).
DSLE (n= 7) Non-DSLE (n= 13) P
Age 29.9 ± 9.2 32.7 ± 12.8 0.61
Female (n) 100% (7) 62% (8) 0.11
Disease duration (years) 5.4 ± 6.8 2.6 ± 3.8 0.25
SLEDAI 19.7 ± 8.7 21.6 ± 16.2 0.78
Anti-DNA (n) 86% (6) 100% (13) 0.35
Anti-SM (n) 57% (4) 62% (8) 1.00
ACA (n) 43% (3) 62% (8) 0.64
LAC (n) 29% (2) 46% (6) 0.64
PSL (mg) 33.9 ± 15.9 46.0 ± 18.9 0.17
PVWM 0 0 N/A
DWM 0 0.31 ± 0.63 0.22
MMSE 29.0 ± 1.3 (n= 6) 28.3 ± 1.9 (n= 9) 0.46
FIQ 80.5 ± 7.6 (n= 6) 83.3 ± 18.6 (n= 11) 0.73
HAMD-17 16.9 ± 6.0 0.54 ± 1.2 1.5 × 10−8
DSLE: SLE with depression; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index;
Anti-DNA: anti-DNA antibodies; Anti-SM: anti-Smith antibodies; ACA: anti-cardiolipin an-
tibodies; LAC: lupus anticoagulant; PSL: prednisolone; PVWM: periventricular white mat-
ter; DWM; deep white matter; MMSE: Mini-Mental State Examination; FIQ: full-scale
intelligence quotient; HAMD-17; Hamilton Depression Rating Scale-17.
For continuous variables, comparisons were made using a two-tailed t-test; comparisons
for dichotomous variables were made using a Fisher's exact test.
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signiﬁcantly higher in the left and rightmedial frontal gyrus of the DSLE
group (Fig. 1). There was no signiﬁcant difference in other segments.
Cerebral glucose metabolism was also compared between the two
groups. A lower level of glucose metabolism (Z N 2.0) was observed in
the DSLE group than in the non-DSLE group on the brain maps (Fig.
2). Using SEE analysis, an ER of over 10%was observed in 8 segments in-
cluding the left and right medial frontal gyri (Table 4).
We also analyzed the CSF test results (Table 5), but these did not re-
veal a signiﬁcant difference between the DSLE and non-DSLE groups.
4. Discussion
In the present study,we foundhypometabolism in every SLE patient,
and glucose metabolism was signiﬁcantly lower in the left and right
medial frontal gyri of SLE patients with major depressive disorder
than in SLE patients without depression.
In the literature, Weiner et al. conducted an FDG-PET study on pa-
tients with NPSLE by using region-of-interest analysis and discovered
hypometabolism in at least one brain region in all patients with NPSLE
(100%) [3]. Additionally, 40% of non-NPSLE patients also exhibited
cerebral hypometabolism. All subjects in the present study, including
non-NPSLE patients, exhibited regions of hypometabolism. These re-
sults indicate that even non-NPSLE subjects frequently have cerebral
dysfunction. Accordingly, it seems difﬁcult to diagnose NPSLE based
only on the presence of hypometabolism in the brain.
Lee et al. also conducted an FDG-PET study on NPSLE patients [4].
They analyzed cerebral metabolism at the lobe level and reported that
NP symptoms did not geographically correlate with FDG-PET ﬁndings.
On the other hand, Komatsu et al. conducted an FDG-PET study on 12
SLE patients, 6 of whomhad psychiatric disorders (3 patients with delu-
sional disorder, 3 patients with mood disorder) [5]. In the Komatsu
study, 16 regions of the cerebrum were evaluated, and it was found
that SLE patients with psychiatric disorders had signiﬁcantly lower re-
gional cerebral glucose metabolism in the prefrontal, inferior parietal
Table 2
Current and prior neuropsychiatric syndromes.
Case
no.
Sex Age Current NP
syndrome
Prior NP syndrome
1 F 43 MDD Aseptic meningitis
2 F 24 MDD None
3 F 19 MDD None
4 F 20 MDD None
5 F 38 MDD None
6 F 34 MDD Seizure disorder
7 F 31 MDD None
8 F 54 Cognitive Dysfunction MDD
9 F 25 None None
10 F 18 None MDD
11 M 48 None None
12 F 21 None None
13 F 41 Cognitive dysfunction Aseptic meningitis, cerebrovascular
disease
14 M 16 None None
15 M 52 None Acute confusional state, cerebrovascular
disease
16 F 38 None Acute confusional state
17 F 27 None None
18 M 24 None None
19 F 33 None None
20 M 28 None None
NP: neuropsychiatric; MDD: major depressive disorder.
Cases 1–7: DSLE group; Cases 8–20: non-DSLE group.
Table 3
Extent ratio of hypometabolism in each segment (mean values ± SD).
Segment DSLE (%) Non-DSLE (%) P
Left hemisphere 11.59 ± 2.68 12.33 ± 5.01 0.72
Right hemisphere 7.29 ± 2.08 9.80 ± 5.46 0.26
Left superior frontal gyrus 19.99 ± 10.25 12.89 ± 8.39 0.11
Right superior frontal gyrus 17.49 ± 7.88 11.69 ± 8.62 0.16
Left middle frontal gyrus 17.51 ± 15.59 19.24 ± 13.70 0.80
Left inferior frontal gyrus 14.61 ± 9.01 12.04 ± 9.14 0.55
Left medial frontal gyrus 16.33 ± 7.49 6.52 ± 6.18 0.0055⁎
Right medial frontal gyrus 18.66 ± 7.88 7.92 ± 5.56 0.0022⁎
Left precentral gyrus 10.36 ± 6.85 9.98 ± 6.78 0.91
Left inferior parietal lobule 22.27 ± 9.17 32.05 ± 30.92 0.43
Left angular gyrus 25.20 ± 27.56 43.66 ± 37.96 0.27
Left supramarginal gyrus 32.46 ± 31.13 48.25 ± 36.76 0.35
Right supramarginal gyrus 13.64 ± 15.47 28.84 ± 31.74 0.25
Left superior temporal gyrus 14.01 ± 12.65 10.57 ± 8.41 0.47
Left middle temporal gyrus 31.54 ± 13.66 27.98 ± 15.26 0.61
Right middle temporal gyrus 10.34 ± 4.95 15.23 ± 16.87 0.47
Left inferior temporal gyrus 15.04 ± 10.08 16.63 ± 15.34 0.81
Left transverse temporal gyrus 11.90 ± 20.89 14.11 ± 31.81 0.87
Left superior occipital gyrus 18.17 ± 23.18 21.32 ± 30.81 0.82
Left cingulate gyrus 13.67 ± 18.34 7.35 ± 10.56 0.34
Right cingulate gyrus 12.39 ± 16.92 5.85 ± 4.27 0.20
Left uncus 10.80 ± 25.39 2.54 ± 3.78 0.25
Right uncus 14.11 ± 29.05 1.78 ± 3.07 0.14
DSLE: SLE with depression.
⁎ p b 0.05.
Fig. 1. Difference in extent ratio. DSLE: SLE with depression; Lt: light; Rt: right; *p b 0.05.
Fig. 2.Brainmap showing signiﬁcant cerebral hypometabolismofDSLE subjects compared
with Non-DSLE subjects. Cerebral glucose metabolism of DSLE group was compared with
that of non-DSLE group by calculating a Z-score ([mean of non-DSLE]− [value of DSLE] /
[standard deviation of non-DSLE]) on a pixel-by-pixel basis. Regions of signiﬁcantly less
metabolism (Z N 2.0) of DSLE group are displayed on a brain map using the color scale
in the ﬁgure. Right lateral (R.LAT), left lateral (L.LAT), superior (SUP), inferior (INF),
anterior (ANT), posterior (POST), right medial (R.MED), and left medial (L.MED) views
are shown. The colored spots exhibit the signiﬁcantly less metabolism in DSLE subjects
compared with non-DSLE subjects. The colored spots are observed in the right (a) and
left medial frontal gyri (b).
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and anterior cingulate regions than SLE patients without psychiatric
symptoms. These results partially matched our ﬁndings. In the
present study, we assessed 62 regions of the cerebrum and found sig-
niﬁcant hypometabolism in the left and right medial frontal gyri of
SLE patients withmajor depressive disorder. Conversely, we evaluat-
ed cerebral metabolism at the hemisphere level but found no differ-
ence between SLE patients with and without depression, which
implies that the total extent of hypometabolism in the cerebrum is
not associated with major depressive disorder. In conclusion, our re-
sults suggest that it is more useful to study depression in SLE by an-
alyzing cerebral metabolism in localized regions than by conducting
an overall cerebral analysis.
As far as primary major depressive disorder is concerned, one
voxel-based meta-analysis of FDG-PET studies of the bilateral insula,
left lentiform nucleus putamen, right caudate and cingulate gyri re-
vealed signiﬁcantly lower levels of glucose metabolism among pa-
tients with primary major depressive disorder than normal healthy
subjects [17]. The medial frontal gyrus was not mentioned in that
study. In the present study, we assessed brain FDG-PET in patients
with SLE and major depressive disorder in comparison with normal
healthy subjects and discovered signiﬁcant hypometabolism in 50
out of 62 regions in the cerebrum of SLE patients with major depres-
sive disorder. Although these results cannot easily be compared with
the above meta-analysis of primary major depressive disorder be-
cause of the difference in analytical methodology, our ﬁndings indi-
cate that the hypometabolic regions of SLE patients with major
depressive disorder are more broadly located in the brain than
those of patients with primary major depressive disorder, and that
the localization of the hypometabolic regions is also different. Fur-
ther research is needed to evaluate the difference in cerebral metab-
olism between SLE patients with major depressive disorder and
patients with primary major depressive disorder.
The present study has some limitations. We enrolled only 20 sub-
jects and did not investigated immunological factors such as inﬂam-
matory cytokines and anti-neuronal antibodies which can have
inﬂuence on NP symptoms and cerebral metabolism. For detailed as-
sessment of the function of the medial frontal gyrus, cognitive func-
tion in each domain should have been investigated using multiple
neuropsychological tests. Moreover, since the present study was
cross-sectional, we were unable to take into account any causal or
risk factors.
5. Conclusions
We performed brain FDG-PET on 20 SLE patients using 3D-SSP anal-
ysis and discovered cerebral hypometabolism in all subjects. Regional
analysis revealed that patients with SLE and major depressive disorder
exhibited a signiﬁcantly lower level of glucosemetabolism in themedial
frontal gyrus than SLE patients without depression. A large-scale and/or
longitudinal study will be needed to conﬁrm our ﬁndings and investi-
gate the mechanism of alterations in cerebral metabolism among SLE
patients with major depressive disorder.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jns.2017.05.059.
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